In millions of Euros, except percentages |
Three months ended March 31, |
Change |
||||||||
2020 IFRS |
Share-based compensation expense and related social charges |
Lease incentives of acquired companies |
2020 Non-IFRS |
2019 IFRS |
Share-based compensation expense and related social charges |
Lease incentives of acquired companies |
2019 Non-IFRS |
IFRS |
Non-IFRS |
|
Cost of revenue |
(196.4) |
3.9 |
0.2 |
(192.3) |
(145.7) |
2.0 |
- |
(143.8) |
35% |
34% |
Research and development |
(230.2) |
13.8 |
0.4 |
(216.0) |
(180.3) |
20.9 |
- |
(159.4) |
28% |
36% |
Marketing and sales |
(331.3) |
13.6 |
0.1 |
(317.6) |
(291.2) |
12.4 |
- |
(278.8) |
14% |
14% |
General and administrative |
(97.4) |
13.0 |
- |
(84.3) |
(76.7) |
11.1 |
- |
(65.6) |
27% |
29% |
Total |
|
44.4 |
0.7 |
|
|
46.3 |
- |
|
(2) Excluding ENOVIA Life Sciences Compliance and Quality Management (Q1 2019: €3.3m)
(3) Including ENOVIA Life Sciences Compliance and Quality Management (Q1 2019: €3.3m)
(4) The non-IFRS percentage increase (decrease) compares non-IFRS measures for the two different periods. In the event there is non-IFRS adjustment to the relevant measure for only one of the periods under comparison, the non-IFRS increase (decrease) compares the non-IFRS measure to the relevant IFRS measure
(5) Based on a weighted average 263.2 million diluted shares for Q1 2020 and 260.5 million diluted shares for Q1 2019